WO2001066697A2 - Serum free cultivation of primate embryonic stem cells - Google Patents

Serum free cultivation of primate embryonic stem cells Download PDF

Info

Publication number
WO2001066697A2
WO2001066697A2 PCT/US2001/006912 US0106912W WO0166697A2 WO 2001066697 A2 WO2001066697 A2 WO 2001066697A2 US 0106912 W US0106912 W US 0106912W WO 0166697 A2 WO0166697 A2 WO 0166697A2
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
culture
growth factor
embryonic stem
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/006912
Other languages
English (en)
French (fr)
Other versions
WO2001066697A3 (en
Inventor
James A. Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24079156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001066697(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2001241973A priority Critical patent/AU2001241973B2/en
Priority to KR1020027011681A priority patent/KR100795760B1/ko
Priority to BR0108507-7A priority patent/BR0108507A/pt
Priority to EP01913296.8A priority patent/EP1261691B1/en
Priority to JP2001565854A priority patent/JP5717311B2/ja
Priority to MXPA02008698A priority patent/MXPA02008698A/es
Priority to AU4197301A priority patent/AU4197301A/xx
Priority to IL15127001A priority patent/IL151270A0/xx
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Priority to HK03106031.5A priority patent/HK1053616B/xx
Priority to CA2402299A priority patent/CA2402299C/en
Priority to NZ520701A priority patent/NZ520701A/en
Publication of WO2001066697A2 publication Critical patent/WO2001066697A2/en
Publication of WO2001066697A3 publication Critical patent/WO2001066697A3/en
Priority to IL151270A priority patent/IL151270A/en
Priority to IS6515A priority patent/IS6515A/is
Priority to NO20024200A priority patent/NO335780B1/no
Anticipated expiration legal-status Critical
Priority to AU2007200575A priority patent/AU2007200575B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Definitions

  • the present invention relates to methods for culturing primate embryonic stem cell cultures and culture media useful therewith.
  • Primate e.g. monkey and human pluripotent embryonic stem cells have been derived from preimplantation embryos. See U.S. patent 5,843,780 and J. Thomson et al .. 282 Science 1145-1147 (1998) . The disclosure of these publications and of all other publications referred to herein are incorporated by reference as if fully set forth herein. Notwithstanding prolonged culture, these cells stably maintain a developmental potential to form advanced derivatives of all three embryonic germ layers . Primate (particularly human) ES cell lines have widespread utility in connection with human developmental biology, drug discovery, drug testing, and transplantation medicine. For example, current knowledge of the post-implantation human embryo is largely based on a limited number of static histological sections. Because of ethical considerations the underlying mechanisms that control the developmental decisions of the early human embryo remain essentially unexplored.
  • ES cell-derived cells include Parkinson's disease, cardiac infarcts, juvenile-onset diabetes mellitus, and leukemia. See e.g. J. Rossant et al. 17 Nature Biotechnology 23-4 (1999) and J. Gearhart, 282 Science 1061-2 (1998).
  • the invention provides a method of culturing primate embryonic stem cells.
  • the culture also has a fibroblast feeder layer.
  • Fibroblast growth factors are essential molecules for mammalian development. There are currently nine known fibroblast growth factor ligands and four signaling fibroblast growth factor receptors therefor (and their spliced variants) . See generally D. Ornitz et al. , 25 J. Biol. Chem. 15292-7 (1996); U.S. patent 5,453,357. Slight variations in these factors are expected to exist between species, and thus the term fibroblast growth factor is not species limited. However, I prefer to use human fibroblast growth factors, more preferably human basic fibroblast growth factor produced from a recombinant gene. This compound is readily available in quantity from Gibco BRL-Life Technologies and others.
  • the culture may still be essentially free of the specified serum even though a discrete component (e.g. bovine serum albumin) has been isolated from serum and then is exogenously supplied.
  • a discrete component e.g. bovine serum albumin
  • bovine serum albumin e.g. bovine serum albumin
  • the primate embryonic stem cells that are cultured using this method are human embryonic stem cells that are true ES cell lines in that they: (i) are capable of indefinite proliferation in vitro in an undifferentiated state; (ii) are capable of differentiation to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm) even after prolonged culture; and (iii) maintain a normal karyotype throughout prolonged culture. They are therefore referred to as being pluripotent.
  • the culturing permits the embryonic stem cells to stably proliferate in culture for over one month
  • stem cells preferably over six months; even more preferably over twelve months
  • the invention provides another method of culturing primate embryonic stem cells.
  • the growth factor is preferably a fibroblast growth factor, it might also be other materials such as certain synthetic small peptides (e.g. produced by recombinant DNA variants or mutants) designed to activate fibroblast growth factor receptors. See generally T. Yamaguchi et al. , 152 Dev. Biol.
  • the invention provides a culture system for culturing primate embryonic stem cells. It has a fibroblast feeder layer and human basic fibroblast growth factor supplied by other than just the fibrololast feeder layer.
  • the culture system is essentially free of animal serum.
  • Yet another aspect of the invention provides cell lines (preferably cloned cell lines) derived using the above method. "Derived” is used in its broadest sense to cover directly or indirectly derived lines. Variability in results due to differences in batches of animal serum is thereby avoided. Further, it has been discovered that avoiding use of animal serum while using fibroblast growth factor can increase the efficiency of cloning. It is therefore an advantage of the present invention to provide culture conditions for primate embryonic stem cell lines where the conditions are less variable and permit more efficient cloning. Other advantages of the present invention will become apparent after study of the specification and claims.
  • KnockOut SR are those described for serum replacements in W0 98/30679.
  • KnockOut SR and either with or without human recombinant basic fibroblast growth factor (bFGF, 4 ng/ml) .
  • the preferred concentration range of bFGF in the culture is between .1 ng/ml to 500 ng/ml.
  • H-9 cultures were dissociated to single cells for 7 minutes with 0.05% trypsin/0.25% EDTA, washed by centrifugation, and plated on mitotically inactivated mouse embryonic fibroblasts (10 5 ES cells per well of a 6-well plate) .
  • individual cells were selected by direct observation under a stereomicroscope and transferred by micropipette to individual wells of a 96 well plate containing mouse embryonic fibroblasts feeders with medium containing 20% serum replacer and 4 ng/ml bFGF.
  • H9 cells were expanded by routine passage every 5-7 days with 1 mg/ml collagenase type IV (Gibco BRL, Rockville, MD) .
  • Six months after derivation H9 cells exhibited a normal XX karyotype by standard G-banding techniques (20 chromosomal spreads analyzed) .
  • 16/20 chromosomal spreads exhibited a normal XX karyotype, but 4/20 spreads demonstrated random abnormalities, including one with a translocation to chromosome 13 short arm, one with an inverted chromosome 20, one with a translocation to the number 4 short arm, and one with multiple fragmentation.
  • H9 cells exhibited normal karyotypes in all 20 chromosomal spreads examined.
  • exogenous bFGF is very important for continued undifferentiated proliferation of primate embryonic stem cells in the absence of animal serum.
  • serum-free medium lacking exogenous bFGF, human ES cells uniformly differentiated by two weeks of culture. Addition of other factors such as LIF (in the absence of bFGF) did not prevent the differentiation.
  • clones for expansion were selected by placing cells individually into wells of a 96 well plate under direct microscopic observation. Of 192 H-9 cells plated into wells of 96 well plates, two clones were successfully expanded (H-9.1 and H-9.2). Both of these clones were subsequently cultured continuously in media supplemented with serum replacer and bFGF.
  • H9.1 and H9.2 cells both maintained a normal XX karyotype even after more than 8 months of continuous culture after cloning.
  • the H-9.1 and H-9.2 clones maintained the potential to form derivatives of all three embryonic germ layers even after long term culture in serum-free medium. After 6 months of culture, H9.1 and H9.2 clones were confirmed to have normal karyotypes and were then injected into SCID-beige mice.
  • Both H9.1 and H9.2 cells formed teratomas that contained derivatives of all three embryonic germ layers including gut epithelium (endoderm) embryonic kidney, striated muscle, smooth muscle, bone, cartilage (mesoderm) , and neural tissue (ectoderm) .
  • the range of differentiation observed within the teratomas of the high passage H9.1 and H9.2 cells was comparable to that observed in teratomas formed by low passage parental H9 cells.
  • the lower cloning efficiency in medium containing serum suggests the presence of compounds in conventionally used serum that are detrimental to stem cell survival, particularly when the cells are dispersed to single cells. Avoiding the use of these compounds is therefore highly desired.
  • the present invention provides methods for culturing primate embryonic stem cells, and culture media for use therewith.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
PCT/US2001/006912 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells Ceased WO2001066697A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2402299A CA2402299C (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
KR1020027011681A KR100795760B1 (ko) 2000-03-09 2001-03-02 영장류 배아 줄기 세포의 무혈청 배양
BR0108507-7A BR0108507A (pt) 2000-03-09 2001-03-02 Cultivo livre de soro de células-tronco embriÈnicas de primatas
EP01913296.8A EP1261691B1 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
JP2001565854A JP5717311B2 (ja) 2000-03-09 2001-03-02 霊長類の胚幹細胞の無血清培養
MXPA02008698A MXPA02008698A (es) 2000-03-09 2001-03-02 Cultivo sin suero de celulas madre embrionarias de primates.
AU4197301A AU4197301A (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
IL15127001A IL151270A0 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
HK03106031.5A HK1053616B (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
AU2001241973A AU2001241973B2 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells
NZ520701A NZ520701A (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells with fibroblast growth factor supplied seperately from fibroblast feeder layers
IL151270A IL151270A (en) 2000-03-09 2002-08-14 Non-serum tumor of primate embryonic stem cells
IS6515A IS6515A (is) 2000-03-09 2002-08-20 Fósturstofnfrumurækt prímata, sem laus er við sermi
NO20024200A NO335780B1 (no) 2000-03-09 2002-09-03 Dyrkningssystem for å dyrke primate embryonale stamceller
AU2007200575A AU2007200575B2 (en) 2000-03-09 2007-02-09 Serum free cultivation of primate embryonic stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/522,030 2000-03-09
US09/522,030 US7005252B1 (en) 2000-03-09 2000-03-09 Serum free cultivation of primate embryonic stem cells

Publications (2)

Publication Number Publication Date
WO2001066697A2 true WO2001066697A2 (en) 2001-09-13
WO2001066697A3 WO2001066697A3 (en) 2002-03-07

Family

ID=24079156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006912 Ceased WO2001066697A2 (en) 2000-03-09 2001-03-02 Serum free cultivation of primate embryonic stem cells

Country Status (14)

Country Link
US (4) US7005252B1 (https=)
EP (1) EP1261691B1 (https=)
JP (3) JP5717311B2 (https=)
KR (1) KR100795760B1 (https=)
CN (1) CN100372928C (https=)
AU (2) AU2001241973B2 (https=)
BR (1) BR0108507A (https=)
CA (1) CA2402299C (https=)
IL (2) IL151270A0 (https=)
IS (1) IS6515A (https=)
MX (1) MXPA02008698A (https=)
NO (1) NO335780B1 (https=)
NZ (1) NZ520701A (https=)
WO (1) WO2001066697A2 (https=)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018654A3 (en) * 2002-08-22 2004-04-08 Celltran Ltd Cell culture surface
WO2004038012A1 (en) * 2002-10-25 2004-05-06 Hunan Hui-Lin Life Technology Co. Ltd The feeder cell layer for in vitro culturing human embryonic stem cells and the method for culturing embryonic stem cells
WO2004078915A3 (en) * 2003-03-05 2004-10-28 Celltran Ltd Cell culture
JP2005501554A (ja) * 2001-09-05 2005-01-20 ジェロン コーポレイション ヒト胚幹細胞を迅速に拡大するための培養系
WO2005090557A1 (ja) * 2004-03-23 2005-09-29 Daiichi Asubio Pharma Co., Ltd. 多能性幹細胞の増殖方法
WO2005113755A1 (en) * 2004-05-21 2005-12-01 Wicell Research Institute, Inc. Feeder independent extended culture of embryonic stem cells
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
WO2006036925A1 (en) * 2004-09-28 2006-04-06 Wicell Research Institute, Inc. Cultivation of primate embryonic stem cells
WO2008018684A1 (en) * 2006-08-11 2008-02-14 Modern Cell & Tissue Technologies Inc. Culture medium for co-culturing of human stem cells and their feeder cells
EP1715033A4 (en) * 2004-02-13 2008-06-11 Asahi Techno Glass Corp MEDIUM FOR PREPARATION OF FEEDER CELLS FOR EMBRYONIC STEM CELLS AND FEEDER CELLS
EP1972685A1 (en) * 2007-03-20 2008-09-24 Universite Rene Descartes (Paris V) Culture medium for gingival fibroblasts
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US7682799B2 (en) 2005-10-06 2010-03-23 University Of Massachusetts Cell division marker
US7687266B2 (en) 2002-01-30 2010-03-30 University Of Edinburgh Pluripotency determining factors and uses thereof
US7820439B2 (en) 2003-09-03 2010-10-26 Reliance Life Sciences Pvt Ltd. In vitro generation of GABAergic neurons from pluripotent stem cells
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
CN102732477A (zh) * 2012-06-15 2012-10-17 江苏瑞思坦生物科技有限公司 人脂肪干细胞无血清基础培养基
WO2012170853A1 (en) 2011-06-10 2012-12-13 Wisconsin Alumni Research Foundation ("Warf") Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
US9074181B2 (en) 2005-06-22 2015-07-07 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
JP2016208999A (ja) * 2004-09-28 2016-12-15 ウィセル リサーチ インスティテュート インコーポレイテッド 霊長類胚性幹細胞の培養
US10421942B2 (en) 2003-12-23 2019-09-24 Viacyte, Inc. Definitive endoderm
US10465162B2 (en) 2004-04-27 2019-11-05 Viacyte, Inc. Anterior endoderm cells and methods of production
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US12123019B2 (en) 2014-06-19 2024-10-22 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413904B2 (en) * 1998-10-23 2008-08-19 Geron Corporation Human embryonic stem cells having genetic modifications
US20100173410A1 (en) * 2000-03-09 2010-07-08 Wicell Research Institute, Inc. Cultivation of Primate Embryonic Stem Cells
WO2003008535A2 (en) * 2001-07-20 2003-01-30 Technion Research And Development Foundation Ltd. Methods of generating human cardiac cells and tissues and uses thereof
US7704736B2 (en) * 2001-11-09 2010-04-27 Trustees Of The University Of Pennsylvania Compositions for the derivation of germ cells from stem cells and methods of use thereof
US20040111285A1 (en) * 2002-04-09 2004-06-10 Mark Germain Method for human pluripotent stem cells
US20070269412A1 (en) * 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
JP4676442B2 (ja) 2003-12-02 2011-04-27 セラヴィー バイオサイエンシズ エルエルシー 神経前駆細胞を増殖させるための組成物および方法
US8586357B2 (en) * 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
WO2005065354A2 (en) * 2003-12-31 2005-07-21 The Burnham Institute Defined media for pluripotent stem cell culture
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
CN102586170B (zh) 2004-07-09 2019-11-29 维亚希特公司 前原条和中内胚层细胞
US8187878B2 (en) * 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
ATE549395T1 (de) * 2004-09-08 2012-03-15 Wisconsin Alumni Res Found Medium und kultur von embryonalen stammzellen
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20060263879A1 (en) * 2004-12-30 2006-11-23 Stemlifeline, Inc. Methods and systems relating to embryonic stem cell lines
WO2006073911A1 (en) * 2004-12-30 2006-07-13 Stemlifeline, Inc. Methods and compositions relating to embryonic stem cell lines
CN1298843C (zh) * 2005-02-07 2007-02-07 十堰市太和医院 不依赖饲养细胞的人胚干细胞培养基
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
JP2009500297A (ja) * 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法
US9101590B2 (en) * 2005-07-29 2015-08-11 Yale University Defined culture conditions of human embryonic stem cells
KR100670616B1 (ko) * 2005-08-25 2007-01-17 주식회사 메디아나전자 상피세포 또는 섬유아세포를 이용한 세포 배양용 인공 배아 및 세포 배양 장치
EP1937801A1 (en) * 2005-09-02 2008-07-02 Agency for Science, Technology and Research Method of deriving mesenchymal stem cells
GB2445338A (en) * 2005-10-07 2008-07-02 Cellartis Ab A method for obtaining a xeno-free HBS cell line
WO2007051038A2 (en) 2005-10-27 2007-05-03 Cythera, Inc. Pdx1-expressing dorsal and ventral foregut endoderm
US7413900B2 (en) * 2005-10-31 2008-08-19 President And Fellows Of Harvard College Immortalized fibroblasts
JP6110048B2 (ja) * 2006-03-02 2017-04-05 ヴィアサイト，インコーポレイテッド 内分泌前駆細胞、膵臓ホルモン発現細胞及びそれらの製造方法
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
AU2007244675A1 (en) 2006-04-28 2007-11-08 Lifescan, Inc. Differentiation of human embryonic stem cells
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US7989204B2 (en) 2006-04-28 2011-08-02 Viacyte, Inc. Hepatocyte lineage cells
CN100465268C (zh) * 2006-05-17 2009-03-04 北京大学 人胚胎干细胞的培养方法及其专用培养基
US7964402B2 (en) 2006-05-25 2011-06-21 Sanford-Burnham Medical Research Institute Methods for culture and production of single cell populations of human embryonic stem cells
US20070292949A1 (en) * 2006-06-20 2007-12-20 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
WO2008048647A1 (en) * 2006-10-17 2008-04-24 Cythera, Inc. Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells
US10829733B2 (en) * 2007-01-04 2020-11-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent human stem cells
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
CA2676044C (en) * 2007-01-30 2019-10-22 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
EP2559756B1 (en) 2007-07-01 2019-12-18 Janssen Biotech, Inc. Single pluripotent stem cell culture
EP3957716A1 (en) 2007-07-18 2022-02-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2584034B8 (en) 2007-07-31 2017-12-06 Lifescan, Inc. Pluripotent stem cell differentiation by using human feeder cells
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
US20100087002A1 (en) * 2008-02-21 2010-04-08 Benjamin Fryer Methods, Surface Modified Plates and Compositions for Cell Attachment, Cultivation and Detachment
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
AU2008355123B2 (en) 2008-04-21 2014-12-04 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
JP5746016B2 (ja) 2008-04-30 2015-07-08 サンバイオ，インコーポレイティド Ｄｎａメチル化における改変を伴う神経再生細胞連邦政府の援助に関する申告適用なし
EP2297319B1 (en) 2008-06-03 2015-10-07 Viacyte, Inc. Growth factors for production of definitive endoderm
US20090298178A1 (en) * 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
AU2009267167A1 (en) * 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
AU2009274517B2 (en) 2008-07-25 2015-03-26 The University Of Georgia Research Foundation, Inc. Compositions for Mesoderm derived ISL1+ Multipotent cells (IMPs), epicardial progenitor cells (EPCs) and multipotent CXCR4+CD56+ cells (C56Cs) and methods of use
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
JP5390624B2 (ja) 2008-11-04 2014-01-15 バイアサイト インク 幹細胞集合体懸濁液組成物、その分化方法
JP2012508584A (ja) * 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
KR101687344B1 (ko) * 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
WO2010096496A2 (en) 2009-02-17 2010-08-26 Memorial Sloan-Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP2421957B1 (en) * 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
CN103952372B (zh) 2009-07-20 2016-10-05 詹森生物科技公司 人胚胎干细胞的分化
WO2011017315A2 (en) 2009-08-03 2011-02-10 Recombinetics, Inc. Methods and compositions for targeted gene modification
PL2494035T3 (pl) * 2009-10-29 2018-07-31 Janssen Biotech, Inc. Pluripotencjalne komórki macierzyste
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
CN102712902B (zh) * 2009-12-23 2019-01-08 詹森生物科技公司 人胚胎干细胞的分化
PH12012501686A1 (en) 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
RU2587634C2 (ru) 2010-05-12 2016-06-20 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
EP2593117B1 (en) 2010-07-12 2019-03-20 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
KR20190027969A (ko) 2010-08-12 2019-03-15 얀센 바이오테크 인코포레이티드 췌장 내분비 전구 세포를 이용한 당뇨병의 치료
CN103154237B (zh) 2010-08-31 2016-03-16 詹森生物科技公司 多能干细胞的分化
PL2853589T3 (pl) 2010-08-31 2018-05-30 Janssen Biotech, Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
EP3372672A1 (en) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9732128B2 (en) 2010-10-22 2017-08-15 Biotime, Inc. Methods of modifying transcriptional regulatory networks in stem cells
BR112013017629A2 (pt) * 2010-12-17 2017-04-18 Biolamina Ab laminina-521 recombinante
EP2801377B1 (en) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
CA2832356C (en) 2011-04-06 2017-12-19 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
EP3693455A1 (en) 2011-11-04 2020-08-12 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
EP3450544A1 (en) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endodrine cells
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
EP2716751A1 (en) 2012-10-08 2014-04-09 BioTime, Inc. Differentiated progeny of clonal progenitor cell lines
AU2013248265B2 (en) 2012-11-08 2018-11-01 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
EP3498824A1 (en) 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
EP3888640B1 (en) 2013-06-05 2025-09-17 Reverse Bioengineering, Inc. Compositions and methods for induced tissue regeneration in mammalian species
RU2016100232A (ru) 2013-06-14 2017-07-17 Дзе Юниверсити Оф Квинсленд Почечные клетки-предшественники
AU2014352773B2 (en) 2013-11-21 2021-04-29 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN104357379B (zh) * 2014-09-30 2017-08-08 刘兴宇 干细胞培养基
CN108779435B (zh) 2015-12-07 2022-05-03 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
US11674952B2 (en) 2016-02-24 2023-06-13 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for Huntington's Disease and uses thereof
US10420803B2 (en) 2016-04-14 2019-09-24 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
KR101877793B1 (ko) * 2016-07-15 2018-07-13 주식회사 엔바이오텍 줄기세포 배양용 무혈청 배지 조성물 및 이를 이용한 줄기세포의 배양 방법
US11268950B2 (en) 2016-09-28 2022-03-08 Organovo, Inc. Use of engineered renal tissues in assays
CN106754652B (zh) * 2017-03-06 2019-04-02 广州润虹医药科技股份有限公司 iPS细胞分化成外胚层祖细胞的无血清诱导培养基及诱导方法
CN106754657B (zh) * 2017-03-28 2022-07-22 北京赛斯达生物技术有限公司 一种猴胚胎干细胞的无血清培养基
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
CN114109294A (zh) * 2020-08-26 2022-03-01 中石化胜利石油工程有限公司管具技术服务中心 闸板拆装装置及其控制系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US670372A (en) * 1898-01-13 1901-03-19 William D Carpenter Process of producing casein products.
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
IL106327A (en) * 1992-07-21 1997-06-10 Perini Fabio Spa Machine and method for the formation of coreless rolls of web material
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
AU3392697A (en) 1996-06-14 1998-01-07 Regents Of The University Of California, The (in vitro) derivation and culture of primate pluripotent stem cells and therapeutic uses thereof
CA2277278A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
GB9722370D0 (en) * 1997-10-22 1997-12-17 Ici Plc Dye sheet cassette and printing apparatus
DE19756864C5 (de) 1997-12-19 2014-07-10 Oliver Brüstle Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
EP1179046B1 (en) 1999-05-07 2006-03-08 University Of Utah Research Foundation Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells
IL129966A (en) * 1999-05-14 2009-12-24 Technion Res & Dev Foundation ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS
US6750581B2 (en) * 2002-01-24 2004-06-15 Visteon Global Technologies, Inc. Automotive alternator stator assembly with rectangular continuous wire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. ORNITZ ET AL., J. BIOL. CHEM., vol. 25, 1996, pages 15292 - 7
J. THOMSON ET AL., SCIENCE, vol. 282, 1998, pages 1145 - 1147
T. YAMAGUCHI ET AL., DEV. BIOL., vol. 152, 1992, pages 75 - 88

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951800B2 (en) 1998-10-23 2015-02-10 Asterias Biotherapeutics, Inc. Primate pluripotent stem cell expansion without feeder cells and in the presence of FGF and matrigel or Engelbreth-Holm-Swarm tumor cell preparation
US8097458B2 (en) 1998-10-23 2012-01-17 Geron Corporation Micro-carrier culture system for rapid expansion of human embryonic stem cells
US8637311B2 (en) 1998-10-23 2014-01-28 Asterias Biotherapeutics, Inc. Human embryonic stem cells genetically modified to contain a nucleic acid and cultured with fibroblast growth factor
US10059939B2 (en) 1998-10-23 2018-08-28 Asterias Biotherapeutics, Inc. Screening methods for human embryonic stem cells
US7659118B2 (en) 1999-08-05 2010-02-09 Abt Holding Company Multipotent adult stem cells
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US10226485B2 (en) 1999-08-05 2019-03-12 Abt Holding Company Multipotent adult stem cells and methods for isolation
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US7439064B2 (en) 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
JP2005501554A (ja) * 2001-09-05 2005-01-20 ジェロン コーポレイション ヒト胚幹細胞を迅速に拡大するための培養系
EP2264145A1 (en) * 2001-09-05 2010-12-22 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US7687266B2 (en) 2002-01-30 2010-03-30 University Of Edinburgh Pluripotency determining factors and uses thereof
WO2004018654A3 (en) * 2002-08-22 2004-04-08 Celltran Ltd Cell culture surface
WO2004038012A1 (en) * 2002-10-25 2004-05-06 Hunan Hui-Lin Life Technology Co. Ltd The feeder cell layer for in vitro culturing human embryonic stem cells and the method for culturing embryonic stem cells
WO2004078915A3 (en) * 2003-03-05 2004-10-28 Celltran Ltd Cell culture
US7820439B2 (en) 2003-09-03 2010-10-26 Reliance Life Sciences Pvt Ltd. In vitro generation of GABAergic neurons from pluripotent stem cells
US10421942B2 (en) 2003-12-23 2019-09-24 Viacyte, Inc. Definitive endoderm
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP1715033A4 (en) * 2004-02-13 2008-06-11 Asahi Techno Glass Corp MEDIUM FOR PREPARATION OF FEEDER CELLS FOR EMBRYONIC STEM CELLS AND FEEDER CELLS
JPWO2005090557A1 (ja) * 2004-03-23 2008-02-07 敏宏 赤池 多能性幹細胞の増殖方法
US7892835B2 (en) 2004-03-23 2011-02-22 Daiichi Sankyo Company, Limited Pluripotent stem cell growing method
WO2005090557A1 (ja) * 2004-03-23 2005-09-29 Daiichi Asubio Pharma Co., Ltd. 多能性幹細胞の増殖方法
US11746323B2 (en) 2004-04-27 2023-09-05 Viacyte, Inc. PDX1 positive foregut endoderm cells and methods of production
US10465162B2 (en) 2004-04-27 2019-11-05 Viacyte, Inc. Anterior endoderm cells and methods of production
CN101018857A (zh) * 2004-05-21 2007-08-15 威塞尔研究所股份有限公司 无饲养细胞的胚胎干细胞的长期培养物
US7514260B2 (en) 2004-05-21 2009-04-07 Wicell Research Institute, Inc. Feeder independent extended culture of embryonic stem cells
GB2429211B (en) * 2004-05-21 2008-12-17 Wicell Res Inst Inc Feeder independent extended culture of embryonic stem cells
WO2005113755A1 (en) * 2004-05-21 2005-12-01 Wicell Research Institute, Inc. Feeder independent extended culture of embryonic stem cells
GB2429211A (en) * 2004-05-21 2007-02-21 Wicell Res Inst Inc Feeder independent extended culture of embryonic stem cells
WO2006036925A1 (en) * 2004-09-28 2006-04-06 Wicell Research Institute, Inc. Cultivation of primate embryonic stem cells
JP2016208999A (ja) * 2004-09-28 2016-12-15 ウィセル リサーチ インスティテュート インコーポレイテッド 霊長類胚性幹細胞の培養
AU2005289597B2 (en) * 2004-09-28 2011-06-09 Wicell Research Institute, Inc. Cultivation of primate embryonic stem cells
GB2433943B (en) * 2004-09-28 2010-06-16 Wicell Res Inst Inc Cultivation of primate embryonic stem cells
JP2017121262A (ja) * 2004-09-28 2017-07-13 ウィセル リサーチ インスティテュート インコーポレイテッド 霊長類胚性幹細胞の培養
GB2433943A (en) * 2004-09-28 2007-07-11 Wicell Res Inst Inc Cultivation of primate embryonic stem cells
US10676714B2 (en) 2005-06-22 2020-06-09 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
US9074181B2 (en) 2005-06-22 2015-07-07 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
US12441983B2 (en) 2005-06-22 2025-10-14 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
US9222939B2 (en) 2005-10-06 2015-12-29 University Of Massachusetts Cell division marker
US8420306B2 (en) 2005-10-06 2013-04-16 University Of Massachusetts Cell division marker
US7682799B2 (en) 2005-10-06 2010-03-23 University Of Massachusetts Cell division marker
WO2008018684A1 (en) * 2006-08-11 2008-02-14 Modern Cell & Tissue Technologies Inc. Culture medium for co-culturing of human stem cells and their feeder cells
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
AU2008201328B2 (en) * 2007-03-20 2014-08-21 Institut National De La Sante Et De La Recherche Medicale Culture medium for gingival fibroblasts
EP1972685A1 (en) * 2007-03-20 2008-09-24 Universite Rene Descartes (Paris V) Culture medium for gingival fibroblasts
WO2012170853A1 (en) 2011-06-10 2012-12-13 Wisconsin Alumni Research Foundation ("Warf") Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
CN102732477B (zh) * 2012-06-15 2013-06-19 江苏瑞思坦生物科技有限公司 人脂肪干细胞无血清基础培养基
CN102732477A (zh) * 2012-06-15 2012-10-17 江苏瑞思坦生物科技有限公司 人脂肪干细胞无血清基础培养基
US12123019B2 (en) 2014-06-19 2024-10-22 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency

Also Published As

Publication number Publication date
US7005252B1 (en) 2006-02-28
KR100795760B1 (ko) 2008-01-21
NO20024200L (no) 2002-09-03
US20060040384A1 (en) 2006-02-23
EP1261691A2 (en) 2002-12-04
NZ520701A (en) 2004-03-26
CA2402299C (en) 2012-12-18
JP2011234735A (ja) 2011-11-24
JP2012005489A (ja) 2012-01-12
KR20030032926A (ko) 2003-04-26
IS6515A (is) 2002-08-20
US7217569B2 (en) 2007-05-15
CN1416345A (zh) 2003-05-07
CA2402299A1 (en) 2001-09-13
HK1053616A1 (zh) 2003-10-31
CN100372928C (zh) 2008-03-05
AU2001241973B2 (en) 2006-11-09
BR0108507A (pt) 2002-12-17
IL151270A0 (en) 2003-04-10
JP2003525625A (ja) 2003-09-02
JP5717311B2 (ja) 2015-05-13
EP1261691B1 (en) 2013-07-31
MXPA02008698A (es) 2003-04-14
WO2001066697A3 (en) 2002-03-07
IL151270A (en) 2008-07-08
US20030190748A1 (en) 2003-10-09
NO20024200D0 (no) 2002-09-03
US20050148070A1 (en) 2005-07-07
NO335780B1 (no) 2015-02-16
AU4197301A (en) 2001-09-17
JP5839666B2 (ja) 2016-01-06

Similar Documents

Publication Publication Date Title
EP1261691B1 (en) Serum free cultivation of primate embryonic stem cells
AU2001241973A1 (en) Serum free cultivation of primate embryonic stem cells
AU2005289597B2 (en) Cultivation of primate embryonic stem cells
US20120178160A1 (en) Cultivation Of Primate Embryonic Stem Cells
AU2007200575B2 (en) Serum free cultivation of primate embryonic stem cells
HK1053616B (en) Serum free cultivation of primate embryonic stem cells
ES2800973T3 (es) Cultivo de células madre embrionarias de primates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 520701

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 151270

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001241973

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 565854

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008698

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018062350

Country of ref document: CN

Ref document number: 1020027011681

Country of ref document: KR

Ref document number: 2402299

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001913296

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001913296

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027011681

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 520701

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 520701

Country of ref document: NZ